Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib

NCT00471328 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

248

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastrointestinal Stromal Tumors

Interventions

DRUG: Nilotinib
OTHER: Best Supportive Care (BSC) +/- imatinib or sunitinib

Sponsor

Novartis Pharmaceuticals